General information of guidelines included in our analysis.

EB: Evidence-based. CB: Consensus-based. HCC: Hepatocellular carcinoma; CLM: Colorectal liver metastases; LM: liver metastases; HM: Hepatic Malignancy; TACE/TAE: Transarterial chemoembolization/Transarterial embolization;BSG:British Society of Gastroenterology;AASLD:American Association for the study of Liver Disease;ESMO: European Society for Medical Oncology; CCO: Cancer Care Ontario;JMH: Japanese Ministry of Health;AOS: Asian Oncology Summit;NCCN: National Comprehensive Cancer Network; APASL: Asian Pacific Association for the study of the Liver; NICE: National Institute for Health and Clinical Excellence;AAGH: Austrian Association of Gastroenterology and Hepatology;EASL-EORTC: European Association for Study of Liver—European Organization for Research and Treatment of Cancer;SASLT/SOS: Saudi Association for the Study of Liver diseases and Transplantation/Saudi Oncology Society;AUGS: Association of Upper Gastrointestinal Surgeons;CMA: Chinese Medical Association;BASL: Belgian Association for the study of the Liver;JSH: Japan Society of Hepatology;CSLCCO: Chinese Societies of Liver Cancer and Clinical Oncology;WGOGG: World Gastroenterology Organization Global Guideline;ICC: International Consensus Conference;SGNLCT: Study Group on New Liver Cancer Therapies; EANM, European Association of Nuclear Medicine;REBOC: Radioembolization Brachytherapy Oncology Consortium;ENETS: European Neuroendocrine Tumor Society;ICO: Institute of Catalan Oncology.AHPBA:Americas Hepatopancreato-Biliary Association,